Derangement of lipid metabolism and its management in renal transplant patients.
Hyperlipidemia is a common clinical finding in postrenal transplant patients. Increasing clinical data suggest that the dyslipidemia seen in these patients is associated with the development of atherosclerotic cardiovascular disease. In addition, recent data suggest that disordered lipid metabolism may be a risk factor for chronic allograft loss. The precise mechanisms whereby dyslipidemia contributes to vascular injury are unknown. No long-term interventional studies of lipid-lowering therapies have been conducted in this patient population. However, a number of short-term studies have shown that the newer antilipemic agents can be safely used in renal transplant patients. Thus, it appears that antilipemic therapy is warranted in renal transplant patients with an atherogenic lipid profile and multiple risk factors.